47 patents
Utility
Formulation for inhibiting formation of 5-HT
17 Oct 23
Drug combinations and their use are disclosed.
Stephen J. Farr, Brooks Boyd
Filed: 19 May 21
Utility
Formulation for inhibiting formation of 5-HT
19 Sep 23
Drug combinations and their use are disclosed.
Stephen J. Farr, Brooks Boyd
Filed: 1 Jul 21
Utility
Fenfluramine compositions and methods of preparing the same
25 Apr 23
Derek J. Londesbrough, Marc W. Andersen
Filed: 27 Jan 21
Utility
Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
28 Mar 23
Provided is a method of treating a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising: determining the patient has been infected with SARS-CoV-2; and administering to the patient a therapeutically effective dose of fenfluramine.
Bradley S. Galer
Filed: 24 Jun 21
Utility
Changing Cognitive Function with Fenfluramine
23 Mar 23
Disclosed herein are methods of improving cognitive function in a patient as measured by, for example, improvement in score on a validated scale that measures cognitive function, such as the Behavior Rating Inventory of Executive Function (BRIEF), by administering the test to a patient and obtaining a pre-treatment test score, treating the patient with fenfluramine or its pharmaceutically acceptable salt, and after treatment, re-administering the test of cognitive function to the patient and obtaining a post-treatment score, to allow observation of an improvement in the test score.
Glenn MORRISON, Arnold GAMMAITONI, Brooks M. BOYD
Filed: 5 May 22
Utility
Fenfluramine for Treatment of Demyelinating Diseases and Conditions
16 Mar 23
Methods of modifying disease progression of a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are also described herein.
John Chang-Eun CHA, Thaddeus Cromwell REEDER
Filed: 25 Aug 22
Utility
Norfenfluramine to Treat Dravet Syndrome
9 Mar 23
Functional analogs of fenfluramine are provided.
Parthena MARTIN, Brooks M. BOYD, Arnold GAMMAITONI, Bradley S. GALER, Gail FARFEL
Filed: 31 Aug 22
Utility
Compositions and methods for treating seizure-induced sudden death
7 Feb 23
5-HT receptor agonists are useful in the treatment of a variety of diseases.
Parthena Martin
Filed: 11 May 18
Utility
Compositions and Methods for Treating Seizure Disorders
24 Nov 22
Functional analogs of fenfluramine are provided.
Parthena MARTIN, Brooks M. BOYD, Arnold GAMMAITONI, Bradley S. Galer, Gail FARFEL
Filed: 17 Jun 22
Utility
Ketogenic diet compatible fenfluramine formulation
4 Oct 22
A method of treating symptoms of a subtype of epilepsy, e.g., Dravet syndrome, in a patient diagnosed with a subtype of epilepsy, by administering to the patient an effective dose of a fenfluramine formulation in combination with a ketogenic diet over a period of time sufficient to reduce or completely eliminate seizures in the patient.
Khawla Abu-Izza, David Hickman, Glenn Morrison, Brooks M. Boyd
Filed: 4 May 20
Utility
Metabolism Resistant Fenfluramine Analogs and Methods of Using the Same
15 Sep 22
Metabolism-resistant fenfluramine analogs are provided.
Stephen J. FARR, Brooks M. BOYD
Filed: 5 Apr 22
Utility
Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
9 Aug 22
Drug combinations and their use are disclosed.
Stephen J. Farr, Brooks Boyd
Filed: 7 Jan 22
Utility
Methods of Treating Doose Syndrome Using Fenfluramine
21 Jul 22
A method of treating and/or preventing symptoms of Doose syndrome in a patient such as a patient previously diagnosed with Doose syndrome, by administering an effective dose of fenfluramine or its pharmaceutically acceptable salt to that patient.
Brooks BOYD, Stephen J. FARR, Bradley GALER
Filed: 5 Apr 22
Utility
Combination Treatment of Specific Forms of Epilepsy
23 Jun 22
Formulations for and methods of treatment of Dravet syndrome that avoid side effects are disclosed.
Peter De Witte, Lieven Lagae, Jo Sourbron, Bradley S. Galer
Filed: 19 Jan 22
Utility
Metabolism resistant fenfluramine analogs and methods of using the same
10 May 22
Metabolism-resistant fenfluramine analogs are provided.
Stephen J. Farr, Brooks M. Boyd
Filed: 8 May 20
Utility
a Formulation for Improving Seizure Control
5 May 22
Described herein is a method of improving seizure control in a patient experiencing uncontrolled seizures persisting 10 minutes or more, comprising administering fenfluramine or a pharmaceutically acceptable salt, base, acid or amine thereof, at a dose of from 0.2 to 1.2 m/kg/day for a period of about 12 hours to about 7 days to a patient having been put into a therapeutic, medically-induced coma via a general anesthetic; and after about 12 hours to about 7 days, weaning the patient from the general anesthetic and assessing whether the seizure control has improved as compared to a pre-treatment time point.
David MILLET, Bradley S. GALER
Filed: 14 Feb 20
Utility
Formulation for Inhibiting Formation of 5-HT2B Agonists and Methods of Using Same
28 Apr 22
Drug combinations and their use are disclosed.
Stephen J. FARR, Brooks BOYD
Filed: 7 Jan 22
Utility
Methods of Treating Thymidine Kinase 2 Deficiency by Administering Deoxycytidine and Deoxythymidine
31 Mar 22
Provided is a method of treating thymidine kinase 2 (TK2) deficiency in a subject by administering deoxycytidine (dC) and deoxythymidine (dT).
Joanne QUAN
Filed: 29 Jul 21
Utility
METHOD OF TREATING PATIENTS INFECTED WITH SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2)
20 Jan 22
Provided is a method of treating a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), comprising: determining the patient has been infected with SARS-CoV-2; and administering to the patient a therapeutically effective dose of fenfluramine.
Bradley S. Galer
Filed: 24 Jun 21
Utility
Methods of Treating Rett Syndrome Using Fenfluramine
13 Jan 22
A method of treating and/or preventing symptoms of Rett syndrome (RTT) in a patient such as a patient previously diagnosed with Rett syndrome, by administering an effective dose of a 5-HT1D, 5-HT2A, 5-HT2C or sigma-1 receptor agonist (e.g., fenfluramine or its pharmaceutically acceptable salt) to that patient.
Bradley S. GALER, Bret MEGARGEL
Filed: 22 Nov 19